ANI Pharmaceuticals Has Launched Kionex (Sodium Polystyrene Sulfonate Suspension USP) For Oral Or Rectal Use
Portfolio Pulse from Benzinga Newsdesk
ANI Pharmaceuticals has launched Kionex (Sodium Polystyrene Sulfonate Suspension USP) for oral or rectal use. The U.S. annual sales for this product total approximately $30.3 million, based on March 2024 moving annual total (MAT) IQVIA data.
May 20, 2024 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ANI Pharmaceuticals has introduced Kionex, a Sodium Polystyrene Sulfonate Suspension USP, for oral or rectal use. This product has an estimated annual sales potential of $30.3 million in the U.S.
The launch of Kionex by ANI Pharmaceuticals is likely to positively impact the company's revenue, given the estimated $30.3 million annual sales potential in the U.S. This new product introduction could enhance the company's market position and financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100